Perspective Therapeutics(CATX) - 2024 Q3 - Quarterly Results

Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET Perspective is conducting a multi-center open-label dose escalation, dose expansion study (clinicaltrials.gov identifier NCT05636618) of [ 212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 ("SSTR2")-positive neuroendocrine tumors ("NETs") who have not received prior peptide receptor radionuclide therapies ("PRRT"). The Company received Fast Track Designation for this program from the U.S. Food and Drug Administrati ...